Aprinoia Therapeutics-preview

Aprinoia

Aprinoia Therapeutics

Private

Cambridge, MassachusettsHealthcare & Life Scienceshttps://aprinoia.com/

Last Round

Grant

Sep 11, 2023

Total Funding Raised

$55.5M

Company Overview

Aprinoia Therapeutics is a biotechnology company that develops diagnostic tools and therapeutics for a broad range of neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Imaging, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

PET imaging tracerneurodegenerative diseasetauopathy diagnosticclinical stage biotechAlzheimer's diseaseprotein degradermonoclonal antibodytheranosticsalpha-synucleinParkinson's diseasePROTACprecision neurosciencebiotech licensingPositron Emission TomographyPETPSPMSA

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aprinoia Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Aprinoia Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Sep 11, 2023
Series C	Dec 28, 2021
Series B	Jan 16, 2018
Seed	May 1, 2015

View all Funding Rounds

Key People

Founding team and executive leadership

Ming-Kuei Jang

Chief Executive Officer

Executive Team

Aprinoia Therapeutics Investors

Notable investors and investment history

Investor	Rounds
TaiAn Technologies Corp.	Series B, Series C
IMM Investment	Series C
DCI Partners	Series A, Series B
Harvest Capital (Suzhou Industrial Park)	Series C
ShangPharma Innovation	Series B
Daol Investment	Series A, Series C, Series B
National Development Fund	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 26, 2026
Monthly visitors grew 648% MoM, from 668 to 5K.
Jan 1, 2026
Monthly visitors grew 181% MoM to 1.9K.

View all signals

Aprinoia Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Aprinoia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aprinoia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts

Employee Range21

Year Founded2015

Last FundingSep 11, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.